Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

Eli Lilly (LLY) shares were up 0.2% in premarket trade, even as it is now facing its first major competitor in China. Suzhou-based Innovent Biologics gained regulatory approval last week for its ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China. Suzhou-based Innovent Biologics secured approval ...

Eli Lilly will expand its manufacturing site in Suzhou China, investing $200 million to produce in-demand drugs Mounjaro and Zepbound.

SAN FRANCISCO and SUZHOU, China, June 3, 2021/ PRNewswire/-- Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines ...

US drug maker Eli Lilly and Co Tuesday celebrated the groundbreaking ceremony for its third insulin plant in Suzhou, East China’s Jiangsu Province, in a bid to further expand its presence in the ...

The newest investment will add 120 new jobs to the plant and brings Lilly’s total investment in the Suzhou site to nearly 15 billion Chinese yuan ($2.1 billion). Lilly isn’t the only drugmaker ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

My first visit to Suzhou for a presentation at a scientific conference was in 2010. ... They launched the first PD-1 clinical trial in China and licensed the overseas rights to Eli Lilly.

Summary. Eddingpharm, a Hong Kong-headquartered China in-licensing company, agreed to pay $375 million to acquire China rights for two off-patent antibiotics from Eli Lilly and the Suzhou factory ...